Phase 2 Study of Yondelis in Men With Advanced Prostate Carcinoma

Trial Profile

Phase 2 Study of Yondelis in Men With Advanced Prostate Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2014

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Apr 2014 According to ClinicalTrials.gov record (NCT00072670); the treatment arms are increased from one (0.58 mg/m2/day) to three (0.58 mg/m2/day OR 1.2 mg/m2/day OR 1.5 mg/m2/day).
    • 07 Apr 2014 According to ClinicalTrials.gov record (NCT00072670); the treatment arms are increased from one (0.58 mg/m2/day) to three (0.58 mg/m2/day OR 1.2 mg/m2/day OR 1.5 mg/m2/day).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top